Form 4: Corcept Therapeutics Executive Hazel Hunt Exercises Options, Sells Shares to Cover Costs
SEC Form 4 Filing
Hazel Hunt, Chief Scientific Officer of Corcept Therapeutics, exercised stock options and sold shares to cover the exercise price and tax obligations on August 1, 2024.
Summary
- On August 1, 2024, Hazel Hunt, the Chief Scientific Officer of Corcept Therapeutics, exercised stock options to acquire 60,000 shares of common stock at a price of $2.81 per share.
- Simultaneously, Hunt sold 34,773 shares at $37.94 per share to cover the exercise price and tax withholding related to the option exercise.
- Following these transactions, Hunt directly owns 118,581 shares of Corcept Therapeutics common stock.
Sentiment
Score: 5
Explanation: This is a neutral disclosure of insider transactions, with no inherent positive or negative implications for the company's overall prospects.
Industry Context
Form 4 filings are standard disclosures required by the SEC when company insiders, like officers and directors, trade their company's stock; this provides transparency to the market.
Stakeholder Impact
- The transaction has a minimal impact on shareholders, as it is a routine exercise of stock options and sale of shares by an executive.
Key Dates
| Date | Description |
|---|---|
| 08/01/2024 | Date of stock option exercise and share sale. |
| 09/11/2024 | Expiration date of the stock options that were exercised. |
| 08/05/2024 | Date of Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.